13 - 15 April 2027Crocus Expo — Moscow
Co-located with
What separates a digital health pilot from a procurement-ready investment? Increasingly, the answer lies in the infrastructure surrounding the tool, not only in the interface a clinician sees.
What separates a digital health pilot from a procurement-ready investment? Increasingly, the answer lies in the infrastructure surrounding the tool, not only in the interface a clinician sees. Health systems and enterprise buyers are assessing telemedicine platforms, AI diagnostics, and healthcare wearables through a harder commercial lens: integration cost, data governance, measurable clinical value, and scale. The market has moved beyond isolated innovation projects. Buyers now want digital health solutions that can sit inside existing operational models without creating new technical debt.
Telemedicine platforms are no longer being sourced as standalone video consultation tools. Enterprise and public-sector buyers are looking for platforms that integrate seamlessly with Electronic Health Record (EHR) systems, booking engines, identity management systems, e-prescribing workflows, and patient portals. The practical question is whether a platform can support continuity of care across multiple sites, departments, and patient groups without forcing clinicians to work across disconnected systems.
This shift is changing procurement criteria. Buyers are placing more weight on application programming interface (API) maturity, data residency, audit trails, language localisation, and uptime commitments. For health systems operating across several markets, data sovereignty can be as important as user experience. The wider shift in enterprise IT is pushing procurement teams towards modular digital architecture rather than fixed software stacks that become expensive to adapt.
Artificial intelligence (AI) diagnostics have entered a more demanding buying cycle. Procurement teams are asking whether tools can demonstrate clinical validity, align with regulated diagnostic pathways, and support decisions that clinicians can interrogate. Accuracy alone no longer carries the case. Buyers want evidence across specific patient populations, imaging types, workflow settings, and operating conditions. For suppliers, this means performance claims must be grounded in real deployment contexts.
One market signal is clear: healthcare organisations are moving AI from experimentation into operating models. A 2026 McKinsey survey of United States healthcare leaders found that half had already implemented generative AI, with integration and return on investment becoming larger barriers than early-stage adoption.
For AI-powered diagnostics, that reinforces a procurement reality: buyers are less impressed by model capability in isolation and more focused on validation, explainability, regulatory alignment, and fit with existing clinical workflows.
Healthcare wearables are being procured for remote patient monitoring, chronic disease management, rehabilitation support, and workforce health programmes. The strongest demand is not for consumer-grade step counters repositioned as healthcare tools. Buyers are specifying wearable medical devices capable of producing reliable, clinically useful data across defined patient cohorts. That includes metrics such as heart rate variability, oxygen saturation, glucose monitoring, fall detection, movement, temperature, and adherence signals.
Procurement teams are also scrutinising the less visible specifications. Battery life affects adherence. Connectivity protocols affect deployment cost. Data accuracy affects clinical trust. Integration with health data platforms affects the device's ability to support scaled care pathways.
For enterprise HealthTech buyers, healthcare wearables only make commercial sense when device data can be interpreted, prioritised, and fed into clinical or operational decision-making. A device that creates additional dashboards without changing clinical or operational actions is unlikely to survive a rigorous procurement process.
Across telemedicine platforms, AI diagnostics, and healthcare wearables, interoperability remains the main procurement pressure point. Buyers across Eurasia and the Commonwealth of Independent States (CIS) often work with mixed infrastructure: legacy hospital systems, national data requirements, private provider networks, and varying procurement maturity. New digital health infrastructure must connect with existing systems rather than assume a clean technical slate.
Data governance is now a commercial filter. Procurement teams are assessing consent management, encryption, role-based access, data retention, transfer rules, and cyber resilience before committing to full-scale procurement. This is especially relevant when remote patient monitoring data, diagnostic outputs, and patient records are shared among providers or jurisdictions. The same principle applies across adjacent sectors such as fintech, where trust depends on secure, compliant data movement. In HealthTech, poor governance does more than raise technical risk; it slows adoption, weakens clinician confidence, and increases the cost of scale.
For HealthTech providers, the strongest commercial opportunities are emerging among organisations with live procurement needs: health systems modernising their digital infrastructure, enterprise groups assessing remote care models, and channel partners seeking credible solutions for regional markets. The challenge is reaching those buyers without spending months filtering low-intent conversations.
ExpoCifra provides a focused route into that demand. Taking place from April 13–15, 2027, at Crocus Expo, Moscow, the platform connects IT and digital solution providers with decision-makers across the Eurasian digital economy. For companies supplying telemedicine platforms, AI diagnostics, healthcare wearables, interoperability tools, or health data infrastructure, submitting an ExpoCifra exhibit enquiry is a practical next step towards building a qualified regional pipeline.